# Clinical biomarkers predicting response to IVIG therapy

## Predictive biomarkers for IVIG response are disease-specific: 
Pre-treatment inflammatory markers (C-reactive protein, liver enzymes, bilirubin) predict resistance in Kawasaki disease, while post-treatment cellular immune markers (NK cells, regulatory T cells) predict response in chronic neurological autoimmune disorders.

## Abstract
Clinical biomarkers predicting IVIG response differ substantially by disease condition and reflect distinct pathophysiological mechanisms. In Kawasaki disease, pre-treatment inflammatory markers consistently predicted resistance: C-reactive protein (cut-offs 7-10 mg/dL), liver transaminases (AST ≥200 IU/L, ALT ≥80 IU/L), and total bilirubin (≥0.9 mg) demonstrated significant associations with non-response in multivariate analyses. Composite prediction scores combining multiple markers achieved 76-78% sensitivity and specificity. Post-treatment inflammatory markers measured 24 hours after infusion showed superior performance, with total leucocyte count >13.1×10⁹/L achieving 91% sensitivity and 89% specificity. In contrast, autoimmune neurological disorders demonstrated no predictive value for inflammatory markers. Instead, post-treatment cellular immune biomarkers proved informative: NK cell markers (CD56bright, KLRB1, KLRK1) measured 24 hours after IVIG initiation significantly discriminated CIDP responders from non-responders (p=0.007-0.027), while regulatory T cell frequency correlated with clinical recovery in Guillain-Barré syndrome. In dermatomyositis, higher baseline cutaneous disease activity predicted better response, whereas higher pulmonary activity predicted lower response. These divergent biomarker profiles reflect condition-specific IVIG mechanisms: acute inflammation suppression in Kawasaki disease versus immune cell modulation in chronic neurological disorders. Clinical consequences of non-response varied substantially, with Kawasaki disease non-responders experiencing coronary artery abnormalities at rates of 38-71% versus 1-5% in responders.

## Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question.

## Results
Ten studies investigating clinical biomarkers for predicting IVIG response were identified, spanning multiple autoimmune and inflammatory conditions. Five studies (50%) had full text available for detailed review.

| Study                     | Full text retrieved? | Medical Condition                          | Sample Size | IVIG Dose                         | Response Definition                                     |
|---------------------------|----------------------|-------------------------------------------|-------------|-----------------------------------|--------------------------------------------------------|
| Y. Levy et al., 1999      | No                   | Systemic lupus erythematosus              | 20          | 2 g/kg monthly over 5 days        | Binary; clinical improvement with decreased SLAM score |
| A. Irgens et al., 2012    | No                   | Myasthenia gravis with worsening weakness | 51          | 2 g/kg divided over 2 days        | Continuous; change in QMG Score at day 14             |
| C. Charles-Schoeman et al., 2025 | No           | Dermatomyositis                          | 95          | 2.0 g/kg every 4 weeks            | Continuous; total improvement score (TIS)              |
| J. Hwang et al., 2010     | No                   | Kawasaki disease                           | 229         | Not specified                      | Binary; responder vs non-responder                     |
| M. Maddur et al., 2017    | Yes                  | Guillain-Barré syndrome                  | 10          | 0.4 g/kg for 3-5 consecutive days  | Continuous; MRC and modified Rankin scores            |
| T. Sano et al., 2006      | No                   | Acute Kawasaki disease                    | 112         | 2 g/kg within 2 days of onset     | Binary; responsive vs non-responsive                    |
| Anne K. Mausberg et al., 2020 | Yes              | Chronic inflammatory demyelinating polyneuropathy | 29 | Not specified, treatment up to 6 months | Binary; INCAT score decline ≥1 point over 6 months  |
| K. Egami et al., 2006     | No                   | Kawasaki disease                           | 320         | 2 g/kg within 9 days of illness   | Binary; resistance vs responder groups                  |
| J. Abe et al., 2008       | No                   | Kawasaki disease                           | Not specified | High-dose (not specified)         | Binary; responsive vs nonresponsive                      |
| Mariko Fukunishi et al., 2000 | No              | Kawasaki disease                           | 82          | High-dose (not specified)         | Binary; defervescence within 5 days                    |

## Predictive Biomarkers by Disease Category
### Kawasaki Disease
Five studies examined biomarkers predicting IVIG resistance in Kawasaki disease, demonstrating substantial heterogeneity in both biomarkers identified and their measurement timing. Pre-treatment inflammatory markers emerged as consistent predictors across multiple studies.

| Study                | Pre-treatment Biomarkers             | Cut-off Values                      | Performance Metrics                                | Post-treatment Biomarkers  |
|----------------------|--------------------------------------|------------------------------------|---------------------------------------------------|-----------------------------|
| T. Sano et al., 2006 | CRP, total bilirubin, AST, ALT, LDH, neutrophil count | CRP ≥7.0 mg, TB ≥0.9 mg, AST ≥200 IU/L | Multivariate p-values: CRP (p=0.009), TB (p<0.001), AST (p=0.002) | Not assessed                 |
| K. Egami et al., 2006 | Age, illness days, platelet count, ALT, CRP | Age <6 months, <4 illness days, platelet ≤30×10¹⁰/L, CRP ≥8 mg/dL, ALT ≥80 IU/L | Prediction score sensitivity 78%, specificity 76% | Not assessed                 |
| Mariko Fukunishi et al., 2000 | CRP, total bilirubin, LDH, gamma-glutamyltranspeptidase, hemoglobin | CRP >10 mg/dL, LDH >590 IU/L, hemoglobin <10 g/dL | Multivariate p-values: CRP (p=.006), LDH (p=.035), TB (p=.046) | Not assessed                 |
| J. Hwang et al., 2010 | Neutrophil differential, CRP         | Pre-treatment: neutrophil >51%     | Total leucocyte >13.1×10⁹/L (sens 91%, spec 89%), neutrophil >51% (sens 91%, spec 76%), total protein <72 g/L (sens 64%, spec 78%) | Not assessed                 |
| J. Abe et al., 2008  | Polycythemia rubra vera 1, G-CSF measured by mRNA and protein levels | Not specified                     | Higher in nonresponders                            | Not assessed                 |

C-reactive protein emerged as the most consistently identified pre-treatment biomarker, appearing in four of five Kawasaki studies. However, optimal CRP cut-off values varied considerably across studies: ≥7.0 mg in Sano et al., ≥8 mg/dL in Egami et al., and >10 mg/dL in Fukunishi et al.. Liver enzymes (AST, ALT) and total bilirubin also demonstrated predictive value in multiple studies.

## Autoimmune Neurological Disorders
Three studies examined biomarkers in distinct neurological conditions, revealing markedly different predictive approaches.

### Guillain-Barré Syndrome
In Guillain-Barré syndrome, Maddur et al. investigated regulatory T cell (Treg) frequency as a post-treatment biomarker. Treg cells were measured by flow cytometry for surface CD4 and intracellular Foxp3 at baseline and weeks 1, 2, and 4-5 post-IVIG. Clinical recovery correlated with Treg cell response, suggesting Treg frequency represents a potential immunological biomarker. Critically, plasma IL-33 levels showed no correlation with clinical response scores (MRC and MRS) at any timepoint, contradicting murine model predictions and highlighting species-specific differences in IVIG mechanisms.

### Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
For chronic inflammatory demyelinating polyneuropathy (CIDP), Mausberg et al. identified natural killer (NK) cell markers measured 24 hours post-IVIG initiation as predictive. CD56bright NK cells and gene transcripts KLRB1 and KLRK1 demonstrated significant association with response, with p-values of 0.007, 0.027, and 0.010 respectively. The observed effects on NK cells occurred almost exclusively in IVIG-responsive patients, with CD56dim cytotoxic NK cells decreasing while CD56bright regulatory NK cells remained stable or increased. Approximately 70% of CIDP patients responded to IVIG, with nonresponders requiring 2-6 months for identification based on lack of INCAT score improvement.

### Myasthenia Gravis
In myasthenia gravis, Irgens et al. used the QMG Score for Disease Severity as both outcome measure and potential severity stratification tool. Patients with baseline QMG >10.5 (more severe disease) demonstrated the greatest improvement, suggesting baseline severity may predict magnitude of response.

## Synthesis
The heterogeneity in predictive biomarkers across conditions reflects fundamental differences in disease pathophysiology, IVIG mechanisms of action, and optimal measurement timing rather than inconsistent or contradictory findings.

**Disease-Specific Biomarker Patterns**
For Kawasaki disease, acute inflammatory markers (CRP, liver enzymes, bilirubin) consistently predicted resistance when measured pre-treatment. This pattern aligns with the disease’s pathophysiology as an acute systemic vasculitis where hyperinflammation drives IVIG resistance.

**Timing of Biomarker Measurement**
The optimal measurement timing varied systematically by condition and biomarker type. Pre-treatment inflammatory markers predicted response in Kawasaki disease, where the goal is suppressing existing inflammation. Post-treatment cellular immune markers (measured 24 hours to weeks after IVIG) predicted response in CIDP and Guillain-Barré syndrome, where the therapeutic mechanism involves immune cell modulation requiring time to manifest.

**Clinical Outcome Implications**
The clinical consequences of IVIG non-response differed markedly by condition. In Kawasaki disease, non-responders faced dramatically elevated risks of coronary artery abnormalities (38-71% versus 1-5% in responders), representing potentially life-threatening complications requiring urgent identification and alternative therapy.

## References
[M. Maddur et al., 2017. Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy. Journal of Neuroinflammation](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-255951252/index.html)
[T. Sano et al., 2006. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. European Journal of Pediatrics](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-21077747/index.html)
[Anne K. Mausberg et al., 2020. NK cell markers predict the efficacy of IV immunoglobulins in CIDP. Neurology: Neuroimmunology & Neuroinflammation](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-222153101/index.html)
[Y. Levy et al., 1999. A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response. Lupus](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-25561402/index.html)
[K. Egami et al., 2006. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. Jornal de Pediatria](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-24236656/index.html)
[J. Abe et al., 2008. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. Journal of Allergy and Clinical Immunology](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-10421555/index.html)
[A. Irgens et al., 2012. Thought Field Therapy (TFT) as a treatment for anxiety symptoms: a randomized controlled trial. Explore](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-267722739/index.html)
[Mariko Fukunishi et al., 2000. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. Jornal de Pediatria](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-8403842/index.html)
[C. Charles-Schoeman et al., 2025. Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study. Rheumatology](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-276212730/index.html)
[J. Hwang et al., 2010. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease. Archives of Disease in Childhood](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-17954853/index.html)